Prevalence of Diabetic Retinopathy in the US in 2021.
Journal
JAMA ophthalmology
ISSN: 2168-6173
Titre abrégé: JAMA Ophthalmol
Pays: United States
ID NLM: 101589539
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
pmc-release:
15
06
2024
medline:
18
8
2023
pubmed:
15
6
2023
entrez:
15
6
2023
Statut:
ppublish
Résumé
Diabetic retinopathy (DR) is a common microvascular complication of diabetes and a leading cause of blindness among working-age adults in the US. To update estimates of DR and vision-threatening diabetic retinopathy (VTDR) prevalence by demographic factors and US county and state. The study team included data from the National Health and Nutrition Examination Survey (2005 to 2008 and 2017 to March 2020), Medicare fee-for-service claims (2018), IBM MarketScan commercial insurance claims (2016), population-based studies of adult eye disease (2001 to 2016), 2 studies of diabetes in youth (2021 and 2023), and a previously published analysis of diabetes by county (2012). The study team used population estimates from the US Census Bureau. The study team included relevant data from the US Centers for Disease Control and Prevention's Vision and Eye Health Surveillance System. Using bayesian meta-regression methods, the study team estimated the prevalence of DR and VTDR stratified by age, a nondifferentiated sex and gender measure, race, ethnicity, and US county and state. The study team defined individuals with diabetes as those who had a hemoglobin A1c level at 6.5% or more, took insulin, or reported ever having been told by a physician or health care professional that they have diabetes. The study team defined DR as any retinopathy in the presence of diabetes, including nonproliferative retinopathy (mild, moderate, or severe), proliferative retinopathy, or macular edema. The study team defined VTDR as having, in the presence of diabetes, severe nonproliferative retinopathy, proliferative retinopathy, panretinal photocoagulation scars, or macular edema. This study used data from nationally representative and local population-based studies that represent the populations in which they were conducted. For 2021, the study team estimated 9.60 million people (95% uncertainty interval [UI], 7.90-11.55) living with DR, corresponding to a prevalence rate of 26.43% (95% UI, 21.95-31.60) among people with diabetes. The study team estimated 1.84 million people (95% UI, 1.41-2.40) living with VTDR, corresponding to a prevalence rate of 5.06% (95% UI, 3.90-6.57) among people with diabetes. Prevalence of DR and VTDR varied by demographic characteristics and geography. US prevalence of diabetes-related eye disease remains high. These updated estimates on the burden and geographic distribution of diabetes-related eye disease can be used to inform the allocation of public health resources and interventions to communities and populations at highest risk.
Identifiants
pubmed: 37318810
pii: 2806093
doi: 10.1001/jamaophthalmol.2023.2289
pmc: PMC10273133
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Comment
Langues
eng
Sous-ensembles de citation
IM
Pagination
747-754Subventions
Organisme : NCCDPHP CDC HHS
ID : U01 DP006444
Pays : United States
Commentaires et corrections
Type : CommentOn
Références
JAMA. 2007 Aug 22;298(8):902-16
pubmed: 17712074
Diabetes. 2015 Feb;64(2):631-42
pubmed: 25204977
Diabetes. 1967 Oct;16(10):728-33
pubmed: 6066644
JAMA. 2021 Jun 25;:
pubmed: 34170288
Diabetes Care. 2016 Sep;39(9):1556-62
pubmed: 27555622
Diabetes Care. 2001 Jul;24(7):1204-9
pubmed: 11423503
Popul Health Manag. 2015 Aug;18(4):283-9
pubmed: 25647516
Ophthalmology. 2004 Jul;111(7):1298-306
pubmed: 15234129
Arch Intern Med. 2007 Sep 24;167(17):1853-60
pubmed: 17893306
Arch Ophthalmol. 2004 Apr;122(4):552-63
pubmed: 15078674
Popul Health Metr. 2018 Jun 15;16(1):9
pubmed: 29903012
N Engl J Med. 2020 Apr 23;382(17):1629-1637
pubmed: 32320570
N Engl J Med. 1999 Aug 26;341(9):667-78
pubmed: 10460819
BMJ Open Diabetes Res Care. 2016 Feb 16;4(1):e000164
pubmed: 26925238
JAMA. 2015 Sep 8;314(10):1021-9
pubmed: 26348752
Diabetes Care. 2023 Jun 1;46(6):1252-1260
pubmed: 37043887
JAMA Ophthalmol. 2014 Nov;132(11):1334-40
pubmed: 25125075
N Engl J Med. 2021 Jun 10;384(23):2219-2228
pubmed: 34107181
JAMA Ophthalmol. 2016 May 01;134(5):563-569
pubmed: 27055063
J Racial Ethn Health Disparities. 2018 Feb;5(1):7-14
pubmed: 28078660
JAMA. 2010 Aug 11;304(6):649-56
pubmed: 20699456
Ethn Dis. 2007 Summer;17(3):529-35
pubmed: 17985509
JAMA Ophthalmol. 2022 Apr 01;140(4):345-353
pubmed: 35238912
N Engl J Med. 2021 Jul 29;385(5):416-426
pubmed: 34320286
Diabet Med. 2012 Sep;29(9):1148-52
pubmed: 22269205
Arch Ophthalmol. 2008 Dec;126(12):1740-7
pubmed: 19064858
Ophthalmic Epidemiol. 2021 Sep 16;:1-13
pubmed: 34530688
Am J Ophthalmol. 2006 Mar;141(3):446-455
pubmed: 16490489
Diabetes Care. 2013 Jun;36(6):1772-4
pubmed: 23704677
Diabetes Care. 1999 Mar;22(3):403-8
pubmed: 10097918
Diabetes Care. 2021 Sep 16;:
pubmed: 34531310
Diabetes. 1968 Mar;17(3):121-3
pubmed: 5638572
JAMA Intern Med. 2021 Nov 1;181(11):1537-1539
pubmed: 34491260